For smaller companies and universities, deciding where to validate a pharma patent can be difficult. Sarah Kostiuk-Smith of Mewburn Ellis looks at the options within the European Patent Convention countries.
Under close scrutiny by regulators, the rules around second medical use patents vary from country to country, explains Jackie Mulryne of Arnold & Porter.
Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada’s federal drug price regulator—and its likely implications.
Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
Tensions between public use, drug laws and regulators make IP around Cannabis a complex situation, explains Ludmila Kawakami and Ana Paula D. C. Couto of Di Blasi, Parente & Associados.
While providing benefits to Mexico’s biologics system, the USMCA may also increase costs for citizens, argues Margarita Guerrero Gonzalez of Uhthoff, Gomez Vega & Uhthoff.
An intervention by Russia’s IP ombudsman seeks to solve the validity issue over secondary patents, but is it needed, asks Maxim Sobolev of Rouse.
In future, the more efficient targeting of treatments to specific patient populations that will actually benefit from them, could offset the price of more expensive but well targeted and effective treatments that will be suitable for increasingly smaller patient populations. Daniel Lim and Anna Jackson of Kirkland & Ellis explain.
LSIPR provides a look behind the scenes of Shire Pharmaceuticals, the Irish company valued at £46 billion by its acquirer Takeda.
An increasing number of pharmaceutical companies are turning to joint representation—where they pool their funds and hire one firm to represent them all—for ANDA litigation. Mark Remus, shareholder at Brinks Gilson & Lione, outlines the pros and cons of this new direction.